ConductScience.org, home

Trial · NCT05729282

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryFasting Plasma Glucose (Absolute Values)Up to Study Day 15Measurement of fasting plasma glucose levels during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: mg/dL).
PrimaryFasting Plasma Glucose (Fold Change)Up to Study Day 15Measurement of fasting plasma glucose during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mg/dL from baseline).
PrimaryFasting Plasma/Serum Insulin (Absolute Values)Up to Study Day 15Measurement of fasting endogenous insulin levels during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: micro-international units \[µIU\] per mL).
PrimaryFasting Plasma/Serum Insulin (Fold Change)Up to Study Day 15Measurement of fasting endogenous insulin levels during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in µIU/mL from baseline).
SecondaryFasting Serum or Plasma Triglycerides (TG) (Absolute Values)Up to Study Day 15Measurement of fasting circulating TG during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: mg/dL).
SecondaryFasting Serum/Plasma Triglycerides (TG) (Fold Change)Up to Study Day 15Measurement of fasting serum TG during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mg/dL from baseline).
SecondaryFasting Plasma Free Fatty Acids (FFA) (Absolute Values)Up to Study Day 15Measurement of fasting plasma FFA (units: mmol/L) during treatment with diazoxide 1 mpk vs 2 mpk vs placebo
SecondaryFasting Plasma Free Fatty Acids (FFA) (Fold Change)Up to Study Day 15Measurement of fasting serum FFA during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mmol/L from baseline)
SecondaryFasting Serum/Plasma Apolipoprotein B (ApoB) (Absolute Values)Up to Study Day 15Measurement of fasting serum/plasma ApoB during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: mg/dL)
SecondaryFasting Serum/Plasma Apolipoprotein B (ApoB) (Fold Change)Baseline and 2 weeks post-treatmentMeasurement of fasting serum/plasma ApoB during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mg/dL from baseline).
OtherContinuous Glucose Monitoring (CGM) ProfileUp to Study Day 15Measurement of interstitial glucose during treatment with diazoxide over the 2-week study course
OtherHepatic de Novo Lipogenesis (Absolute Values)assessed at 1 week and 2 weeks after treatmentPercent incorporation of newly synthesized fatty acids into serum or VLDL TG (units: %)
OtherHepatic de Novo LipogenesisUp to Study Day 15Incorporation of newly synthesized fatty acids into serum or VLDL TG relative to placebo, reported as a ratio
OtherDeuterium Tracer Enrichment in Body Water (Measured in Blood)Up to Study Day 15Enrichment of total body water with deuterated water (2H2O/D2O) (units: %)
OtherDeuterium Tracer Enrichment in Body Water (Measured in Saliva)Up to Study Day 15Enrichment of total body water with deuterated water (2H2O/D2O) (units: %)

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05729282/registered